Abstract
Introduction & Objectives
In systemic therapy trials, a decreasing neutrophil-to-lymphocyte ratio (NLR) after
treatment for metastatic renal cell carcinoma (RCC) has been associated with improved
oncologic outcomes. Paradoxically, for patients with localized RCC treated with upfront
surgery the opposite effect has been reported. We thus aimed to evaluate NLR dynamics
on localized RCC recurrence.
Materials and Methods
Treatment naïve patients with localized RCC managed surgically between 2005 and 2020
were included. Preoperative NLR was calculated within 6-weeks prior to surgery and
postoperative NLR was calculated between 4 and twelve-weeks after surgery. Patients
were followed for disease recurrence, noting metastatic sites and postoperative infections.
Cox regression were used to determine whether the relative change in postoperative
NLR was associated with metastasis-free survival (MFS) and cancer-specific survival
(CSS), adjusted for preoperative NLR.
Results
In the cohort of 3310 patients, 996 (30%) had postoperative NLR available. These patients
generally had more advanced disease, with 100 developing metastases and 38 dying from
kidney cancer. Median MFS follow-up was 4.4 years. Decreasing 2-month postoperative
NLR was associated with non–statistically significant worse MFS and CSS (HR 0.79,
95% 0.50, 1.24, P = .3; HR 0.83, 95% C.I. 0.40, 1.73; P = .6). On sensitivity analysis, across all NLR measurements, with NLR as a time-dependent
covariate, results were similar, with a declining NLR associated with adverse MFS
(HR 0.85, 95% CI 0.69, 1.30, P-value = .10), though not meeting conventional levels of significance.
Conclusion
In higher-risk localized RCC patients, postoperative NLR is not suitable as a biomarker
for predicting recurrences.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2021.CA Cancer J Clin. 2021; 71: 7-33https://doi.org/10.3322/caac.21654
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.Cancer. 2003; 97: 1663-1671https://doi.org/10.1002/cncr.11234
- A postoperative prognostic nomogram for renal cell carcinoma.J Urol. 2001; 166: 63-67
- Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.Immunotherapy. 2019; 11: 631-643https://doi.org/10.2217/imt-2018-0175
- The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: a review.Urol Oncol. 2017; 35: 135-141https://doi.org/10.1016/j.urolonc.2017.01.016
- Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.Urol Oncol. 2019; 37: 811.e9-811.e16https://doi.org/10.1016/j.urolonc.2019.07.011
- Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy.Oncotarget. 2018; 9: 14296-14305https://doi.org/10.18632/oncotarget.24507
- Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.J Immunother Cancer. 2018; 6: 5https://doi.org/10.1186/s40425-018-0315-0
- Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma.J Urol. 2012; 187: 411-417https://doi.org/10.1016/j.juro.2011.10.026
- Postoperative better than preoperative c-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma.Urology. 2010; 76: 766.e1-766.e5https://doi.org/10.1016/j.urology.2010.01.052
- The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer.Sci Rep. 2018; 8: 9453https://doi.org/10.1038/s41598-018-27896-y
- Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.Urol Oncol. 2015; 33: 67.e1-67.e7https://doi.org/10.1016/j.urolonc.2014.06.010
- Post-operative neutrophil-lymphocyte ratio predicts complications following colorectal surgery.Int J Surg. 2007; 5: 27-30https://doi.org/10.1016/j.ijsu.2006.05.013
- The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma.Can J Urol. 2016; 23: 8151-8154
- Impact of perioperative infection on cancer specific survival after nephrectomy for renal cell carcinoma.J Urol. 2017; 198: 1027-1032https://doi.org/10.1016/j.juro.2017.05.070
- The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.Urol Oncol. 2019; 37: 916-923https://doi.org/10.1016/j.urolonc.2019.09.006
- Change in Neutrophil-to-Lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy.Eur Urol. 2016; 70: 358-364https://doi.org/10.1016/j.eururo.2016.02.033
- Can Neutrophil/Lymphocyte ratio be a predictor for bone metastases of solid tumors?.World J Nucl Med. 2016; 15: 196-199https://doi.org/10.4103/1450-1147.174711
Article Info
Publication History
Published online: May 25, 2022
Accepted:
May 20,
2022
Received:
March 28,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
